Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (ASBP), a Delaware corporation and emerging growth company, on January 13, 2026. The report covers events occurring on January 7, 2026. The Company's common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols ASBP and ASBPW, respectively.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the departure of a Director:
- Event: Surendra Ajjarapu notified the Board of Directors of his intention to step down from the role of Director.
- Effective Date: January 7, 2026 (immediate).
- Reason: The resignation is not due to any disagreement with the Company, the Board of Directors, or any member of management.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future operations, specific risks, contingencies, or unusual items beyond the director resignation.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the immediate resignation of Surendra Ajjarapu.
- Confirm whether the Company intends to appoint a replacement Director to fill the vacancy.
- Review subsequent filings for any impact on corporate governance or strategic direction.